132 related articles for article (PubMed ID: 37276908)
1. Synergistically enhanced cancer immunotherapy by combining protamine-based nanovaccine with PD-L1 gene silence nanoparticle.
Jiang M; Chen W; Sun Y; Zeng J; Ma L; Gong J; Guan X; Lu K; Zhang W
Int J Biol Macromol; 2023 Jul; 242(Pt 4):125223. PubMed ID: 37276908
[TBL] [Abstract][Full Text] [Related]
2. Cooperating minimalist nanovaccine with PD-1 blockade for effective and feasible cancer immunotherapy.
Jiang M; Zhao L; Cui X; Wu X; Zhang Y; Guan X; Ma J; Zhang W
J Adv Res; 2022 Jan; 35():49-60. PubMed ID: 35003793
[TBL] [Abstract][Full Text] [Related]
3. Highly Enhanced Antitumor Immunity by a Three-Barreled Strategy of the l-Arginine-Promoted Nanovaccine and Gene-Mediated PD-L1 Blockade.
Hu Y; Lin L; Chen J; Hao K; Zhang S; Guo X; Guo Z; Tian H; Chen X
ACS Appl Mater Interfaces; 2020 Sep; 12(37):41127-41137. PubMed ID: 32808767
[TBL] [Abstract][Full Text] [Related]
4. Efficient PD-L1 gene silence promoted by hyaluronidase for cancer immunotherapy.
Guan X; Lin L; Chen J; Hu Y; Sun P; Tian H; Maruyama A; Chen X
J Control Release; 2019 Jan; 293():104-112. PubMed ID: 30476528
[TBL] [Abstract][Full Text] [Related]
5. Combination of Sunitinib and PD-L1 Blockade Enhances Anticancer Efficacy of TLR7/8 Agonist-Based Nanovaccine.
Kim H; Khanna V; Kucaba TA; Zhang W; Ferguson DM; Griffith TS; Panyam J
Mol Pharm; 2019 Mar; 16(3):1200-1210. PubMed ID: 30620878
[TBL] [Abstract][Full Text] [Related]
6. Coadministration of iRGD peptide with ROS-sensitive nanoparticles co-delivering siFGL1 and siPD-L1 enhanced tumor immunotherapy.
Wan WJ; Huang G; Wang Y; Tang Y; Li H; Jia CH; Liu Y; You BG; Zhang XN
Acta Biomater; 2021 Dec; 136():473-484. PubMed ID: 34571271
[TBL] [Abstract][Full Text] [Related]
7. A generally minimalist strategy of constructing biomineralized high-efficiency personalized nanovaccine combined with immune checkpoint blockade for cancer immunotherapy.
Zhang S; Feng Y; Meng M; Li Z; Li H; Lin L; Xu C; Chen J; Hao K; Tang Z; Tian H; Chen X
Biomaterials; 2022 Oct; 289():121794. PubMed ID: 36113330
[TBL] [Abstract][Full Text] [Related]
8. Anti-PD-L1 peptide-conjugated prodrug nanoparticles for targeted cancer immunotherapy combining PD-L1 blockade with immunogenic cell death.
Moon Y; Shim MK; Choi J; Yang S; Kim J; Yun WS; Cho H; Park JY; Kim Y; Seong JK; Kim K
Theranostics; 2022; 12(5):1999-2014. PubMed ID: 35265195
[No Abstract] [Full Text] [Related]
9. Highly enhanced cancer immunotherapy by combining nanovaccine with hyaluronidase.
Guan X; Chen J; Hu Y; Lin L; Sun P; Tian H; Chen X
Biomaterials; 2018 Jul; 171():198-206. PubMed ID: 29698869
[TBL] [Abstract][Full Text] [Related]
10. Immune checkpoint silencing using RNAi-incorporated nanoparticles enhances antitumor immunity and therapeutic efficacy compared with antibody-based approaches.
Won JE; Byeon Y; Wi TI; Lee CM; Lee JH; Kang TH; Lee JW; Lee Y; Park YM; Han HD
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35228265
[TBL] [Abstract][Full Text] [Related]
11. Cancer Immunotherapy of TLR4 Agonist-Antigen Constructs Enhanced with Pathogen-Mimicking Magnetite Nanoparticles and Checkpoint Blockade of PD-L1.
Traini G; Ruiz-de-Angulo A; Blanco-Canosa JB; Zamacola Bascarán K; Molinaro A; Silipo A; Escors D; Mareque-Rivas JC
Small; 2019 Jan; 15(4):e1803993. PubMed ID: 30569516
[TBL] [Abstract][Full Text] [Related]
12. PD-L1 degradation pathway and immunotherapy for cancer.
Gou Q; Dong C; Xu H; Khan B; Jin J; Liu Q; Shi J; Hou Y
Cell Death Dis; 2020 Nov; 11(11):955. PubMed ID: 33159034
[TBL] [Abstract][Full Text] [Related]
13. Regulating the immunosuppressive tumor microenvironment to enhance breast cancer immunotherapy using pH-responsive hybrid membrane-coated nanoparticles.
Gong C; Yu X; Zhang W; Han L; Wang R; Wang Y; Gao S; Yuan Y
J Nanobiotechnology; 2021 Feb; 19(1):58. PubMed ID: 33632231
[TBL] [Abstract][Full Text] [Related]
14. Facile preparation of a metal-phenolic network-based lymph node targeting nanovaccine for antitumor immunotherapy.
Su Q; Liu Z; Du R; Chen X; Chen L; Fu Z; Luo X; Yang Y; Shi X
Acta Biomater; 2023 Mar; 158():510-524. PubMed ID: 36603733
[TBL] [Abstract][Full Text] [Related]
15. Novel Nanotherapeutics for Cancer Immunotherapy by PD-L1-Aptamer-Functionalized and Fexofenadine-Loaded Albumin Nanoparticles.
Lai X; Yao F; An Y; Li X; Yang XD
Molecules; 2023 Mar; 28(6):. PubMed ID: 36985529
[TBL] [Abstract][Full Text] [Related]
16. Co-inhibition of the TGF-β pathway and the PD-L1 checkpoint by pH-responsive clustered nanoparticles for pancreatic cancer microenvironment regulation and anti-tumor immunotherapy.
Wang Y; Gao Z; Du X; Chen S; Zhang W; Wang J; Li H; He X; Cao J; Wang J
Biomater Sci; 2020 Sep; 8(18):5121-5132. PubMed ID: 32820750
[TBL] [Abstract][Full Text] [Related]
17. Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure).
Kim JM; Chen DS
Ann Oncol; 2016 Aug; 27(8):1492-504. PubMed ID: 27207108
[TBL] [Abstract][Full Text] [Related]
18. A tumor microenvironment responsive biodegradable CaCO
Liu Y; Pan Y; Cao W; Xia F; Liu B; Niu J; Alfranca G; Sun X; Ma L; de la Fuente JM; Song J; Ni J; Cui D
Theranostics; 2019; 9(23):6867-6884. PubMed ID: 31660074
[TBL] [Abstract][Full Text] [Related]
19. A tumor extracellular pH-sensitive PD-L1 binding peptide nanoparticle for chemo-immunotherapy of cancer.
Zhu W; Bai Y; Zhang N; Yan J; Chen J; He Z; Sun Q; Pu Y; He B; Ye X
J Mater Chem B; 2021 May; 9(20):4201-4210. PubMed ID: 33997867
[TBL] [Abstract][Full Text] [Related]
20. Emerging Role of Ubiquitination in the Regulation of PD-1/PD-L1 in Cancer Immunotherapy.
Hu X; Wang J; Chu M; Liu Y; Wang ZW; Zhu X
Mol Ther; 2021 Mar; 29(3):908-919. PubMed ID: 33388422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
